| 标题 |
A dual PD-1/PD-L1 bispecific antibody LY3434172 (Reozalimab) provides superior checkpoint inhibition and T cell activation vs combination monotherapies |
| 网址 | |
| DOI | |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)